Medically reviewed by Dr. Hyun Joon Lee, MD. Board-certified in Family Medicine, Integrative Holistic Medicine, and Obesity Medicine. Founder and Medical Director, SeeBeyond Medicine.
What These Medications Are
A GLP-1 receptor agonist is a medication that mimics glucagon-like peptide-1, a hormone released by the gut after eating. It slows the rate at which the stomach empties and acts on brain regions that regulate appetite. Tirzepatide adds a second target, the GIP receptor.
That distinction sits underneath most of the confusion in press coverage. Semaglutide and tirzepatide are not the same drug at a different price, and they were not studied against the same comparator.
The sections below move from biology to prescribing. Mechanism first, then the labeled indications, then candidacy, then the trial data, then the workup that turns a prescription into a plan.
How GLP-1 and Dual GIP/GLP-1 Medications Work
Your gut releases GLP-1 after a meal. The hormone signals the pancreas to release insulin in a glucose-dependent way, suppresses glucagon, and slows gastric emptying.
The appetite effect runs through the brain. GLP-1 receptors sit in the brainstem and in hypothalamic nuclei that govern homeostatic feeding, so activating them changes hunger at the source rather than at the plate.
A systematic review of randomized trials on appetite parameters and gastric emptying found that GLP-1 analogues reduce hunger and energy intake while slowing gastric emptying. Fullness arrives earlier in a meal and persists longer after it.
This is why patients describe the effect as the food noise going quiet. Intake falls without a daily act of restraint, which is a different mechanism from appetite suppressants that work on stimulation.
Tirzepatide activates the GIP receptor alongside the GLP-1 receptor. GIP is the other major incretin hormone, and GIP-receptor-expressing cells in the hypothalamus also regulate food intake, which gives the dual agonist a second route into the same system.
Slowed gastric emptying carries clinical consequences beyond satiety. A review of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide describes retained gastric contents as a concern during endoscopy and general anesthesia. Tell any surgeon or gastroenterologist that you are on one of these medications.
The Approved Agents and What They Are Approved For
Semaglutide 2.4 mg is marketed as Wegovy. The FDA prescribing information indicates it as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
The label sets the entry criteria by body mass index. An initial BMI of 30 kg/m² or greater qualifies on its own, and a BMI of 27 kg/m² or greater qualifies in the presence of at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.
Semaglutide later gained a second indication. The FDA approved it to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight.
That trial randomized more than 17,600 participants. Major adverse cardiovascular events occurred in 6.5% of the semaglutide group compared with 8% of the placebo group.
Tirzepatide is marketed as Zepbound for weight management and as Mounjaro for type 2 diabetes. The FDA approved Zepbound for chronic weight management in November 2023 using the same BMI thresholds and the same requirement for at least one weight-related condition at the lower threshold.
A third indication followed. In December 2024 the FDA approved tirzepatide as the first drug treatment for moderate to severe obstructive sleep apnea in adults with obesity, used alongside a reduced-calorie diet and increased physical activity.
For anyone whose sleep study sits in the same chart as their weight, that approval changes the conversation. Sleep apnea stops being a downstream consequence and becomes part of the treatment target.
Who Qualifies, and Who Should Not Take These Drugs
Candidacy starts with the BMI thresholds above, and it does not end there. BMI is a screening number, not a diagnosis, and a physician board-certified in Obesity Medicine reads it alongside body composition, metabolic labs, and medical history.
Both labels carry the same absolute contraindication. Neither medication is appropriate for patients with a personal or family history of medullary thyroid carcinoma, or for patients with Multiple Endocrine Neoplasia syndrome type 2.
The Zepbound prescribing information also carries warnings for pancreatitis, gallbladder disease, acute kidney injury, diabetic retinopathy in patients with type 2 diabetes, and suicidal behavior or thinking.
Hypoglycemia risk rises in a specific situation. Patients with diabetes taking a GLP-1 alongside insulin or an insulin secretagogue such as a sulfonylurea need their other medications adjusted, not simply layered.
Semaglutide-containing products should not be combined with each other or with another GLP-1 receptor agonist. This matters more than it used to, because compounded and imported products have made accidental duplication easier.
Pregnancy, planned pregnancy, and a history of pancreatitis all warrant a separate conversation. So does a history of an eating disorder, where appetite suppression interacts with something the medication was never designed to treat.
What the Registration Trials Reported
The semaglutide evidence rests on the STEP program. In STEP 1, 1,961 adults with overweight or obesity and without diabetes received once-weekly semaglutide 2.4 mg or placebo for 68 weeks, alongside lifestyle intervention.
Mean body weight change was −14.9% with semaglutide and −2.4% with placebo. Roughly 86% of participants on the drug lost at least 5% of their body weight, compared with about 32% on placebo.
The tirzepatide evidence rests on SURMOUNT. In SURMOUNT-1, participants with obesity and without diabetes received 5 mg, 10 mg, or 15 mg of tirzepatide once weekly for 72 weeks.
Mean weight reduction reached 19.5% at the 10 mg dose and 20.9% at the 15 mg dose, against 3.1% with placebo. The trial authors called that degree of reduction unusually large for an antiobesity medication.
Read those two trials side by side and the temptation is to declare a winner. Resist it. Different trial lengths, different populations, different placebo responses, and different estimands all sit between the two numbers.
Reading the Head-to-Head Evidence Carefully
One trial did compare them directly. SURMOUNT-5 randomized 751 adults with obesity and without diabetes to the maximum tolerated dose of tirzepatide or the maximum tolerated dose of semaglutide for 72 weeks.
Mean body weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Waist circumference fell further in the tirzepatide group as well.
Three caveats belong with that result. The trial was open-label rather than blinded, it enrolled adults without type 2 diabetes, and greater weight reduction is not automatically the same thing as better long-term health outcomes.
The cardiovascular outcome data currently sits with semaglutide. Tirzepatide produced more weight loss in a direct comparison, and semaglutide holds the FDA indication for reducing major adverse cardiovascular events.
Tolerability also splits the picture. Gastrointestinal adverse events leading to discontinuation occurred in about 5.6% of the semaglutide group and about 2.7% of the tirzepatide group in SURMOUNT-5.
The practical conclusion is unglamorous. The better drug is the one that matches your comorbidities, your tolerance, your insurance coverage, and your goals, which is a clinical judgment rather than a ranking.
The Workup That Turns a Prescription into a Plan
Test, don't guess. A prescription written from a BMI number alone treats a symptom, and the questions that determine whether the medication works are usually sitting in bloodwork nobody ordered.
Thyroid status comes first. Untreated hypothyroidism slows resting metabolic rate and blunts response to any weight intervention, and it needs correcting before the medication gets blamed for a plateau.
Fasting insulin and glucose describe the metabolic starting point. Two patients at the same weight can sit at opposite ends of the insulin resistance spectrum, and that difference shapes both the expected trajectory and the nutrition plan attached to it.
Sex hormone status matters in both directions. Perimenopausal changes and low testosterone each alter body composition independently of intake, which is why hormone replacement therapy sometimes belongs in the same plan as a GLP-1.
Nutrient status shapes tolerability. Individual optimal nutrition profile testing identifies deficiencies that get worse when total intake drops by a third, which is exactly what these medications cause.
At SeeBeyond Medicine, this workup precedes the prescription rather than following it. The practice has treated more than 20,000 patients since opening in 2006, and patients of the practice have lost more than 400,000 pounds collectively.
Our medical weight loss program is directed by a physician board-certified in Obesity Medicine, with Vanessa Rogers, MPAS, PA-C running much of the day-to-day hormone and GLP-1 follow-up. There is no generic one size fits all approach.
Dose Escalation and Side Effects
Both medications start low and increase in steps. SURMOUNT-1 escalated participants at four-week intervals from a starting dose toward their assigned maintenance dose, which is the general shape of clinical practice as well.
The reason for the slow climb is tolerability rather than caution for its own sake. Gastrointestinal effects cluster at dose increases, and a patient who escalates too quickly often abandons a medication that would have worked at a slower pace.
Nausea, vomiting, diarrhea, and constipation are the effects patients report most. They tend to be dose-related and tend to settle, though they are the leading reason for discontinuation in the trials.
Managing them is largely mechanical: meal size, meal timing, protein sequencing, hydration, and knowing which symptoms warrant a call rather than a workaround. Our guide to managing GLP-1 side effects covers the protocol in detail.
Some symptoms are not side effects to ride out. Severe or persistent abdominal pain, signs of gallbladder disease, and any change in mood or thinking need a same-week clinical conversation.
Ask your physician about dosing rather than adjusting on your own. Nothing in this article is a dosing instruction.
Protecting Muscle While You Lose Fat
Every caloric deficit costs some lean mass. The question is proportion, and the proportion is measurable.
A body composition substudy within SURMOUNT-1 used DXA scanning in 160 participants at baseline and at week 72. Weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9% in the tirzepatide group.
Expressed as a share of total loss, that came to roughly 74% fat and 26% lean, which closely matched the placebo group's split. The drug did not skew the composition of the loss; it increased the size of it.
That finding cuts both ways. The proportion is ordinary, and the absolute lean mass loss is larger simply because the total loss is larger.
Protein intake and resistance training are the two levers that change the ratio. Nutrition counseling sets the protein target against your actual body weight and activity, and our article on preventing muscle loss on a GLP-1 covers the training side.
Body composition testing rather than scale weight is what makes this visible. A pound is not a unit of progress if you do not know what tissue it came from.
The Maintenance Question
The hardest question about these medications is what happens when you stop. The trials answered it directly, and the answer is uncomfortable.
The STEP 1 trial extension followed participants for a year after treatment withdrawal. Mean weight loss of 17.3% at week 68 gave way to a regain of 11.6 percentage points by week 120, leaving a net loss of 5.6%.
Participants regained roughly two-thirds of what they had lost. Cardiometabolic improvements reverted toward baseline across most measured variables.
The authors framed this as confirmation that obesity is a chronic condition. Withdrawal of an effective treatment produces recurrence, which is how chronic disease behaves rather than how a failed intervention behaves.
That reframing changes the planning conversation. The question stops being how fast the weight comes off and becomes what the plan looks like in year three.
Some patients taper toward a maintenance dose, some continue indefinitely, and some transition with intensive nutrition and training support. Our article on stopping a GLP-1 and keeping weight off walks through the options and the evidence behind each.
Sleep, stress, and alcohol belong in the same plan. None of them show up in a trial endpoint, and all of them determine whether the maintenance phase holds.
Key Takeaways
- GLP-1 receptor agonists slow gastric emptying and act on appetite signaling, which reduces intake without relying on willpower.
- Tirzepatide acts on two receptor pathways, and head-to-head evidence should be read carefully rather than summarized as one drug winning.
- Eligibility is defined by BMI thresholds with or without weight-related conditions, and by a review of contraindications.
- Baseline labs matter because thyroid, insulin, and hormone status shape both dosing and expectations.
- The medication works best inside a plan that also addresses protein intake, resistance training, sleep, and stress.
Related Resources
The three articles below go deeper on the subtopics this guide introduces.
- Managing GLP-1 side effects covers nausea, constipation, and the symptoms that warrant a call.
- Preventing muscle loss on a GLP-1 covers protein targets, resistance training, and body composition tracking.
- Stopping a GLP-1 and keeping weight off covers tapering, maintenance dosing, and the regain data.
Service pages for the clinical side of the program:
- Physician-supervised GLP-1 weight loss therapy and tirzepatide therapy describe how each agent is prescribed and monitored.
- Medical weight loss program covers the full program structure, including nutrition counseling.
- Individual optimal nutrition profile testing and hormone replacement therapy cover the workup and the adjacent treatments.
- Physician-formulated supplements support protein and micronutrient targets during active weight loss.
A GLP-1 prescription is the easiest part of this to obtain and the hardest part to get right alone. The variables that decide the outcome are your labs, your protein intake, your training, and your plan for year three.
If you want those variables mapped before you start, schedule a consultation at our Scarsdale, NY office in Westchester County or our Greenwich, CT office in Fairfield County. Telemedicine visits are available for intake and follow-up.
This article is for general education and does not replace a medical evaluation. Treatment decisions depend on your history, medications, and lab work. Speak with a qualified clinician before starting, stopping, or changing any therapy.
